

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10612179
	Filing Date		2003-07-02
	First Named Inventor	ROLAND KREUTZER	
	Art Unit	1635	
	Examiner Name	TRACY ANN VIVLEMORE	
	Attorney Docket Number	A2038-706120	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

Receipt date: 09/16/2008 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10612179
	Filing Date		2003-07-02
	First Named Inventor	ROLAND KREUTZER	
	Art Unit	1635	
	Examiner Name	TRACY ANN VIVLEMORE	
	Attorney Docket Number	A2038-706120	

/T.V./	1	FERRY ET AL., "Retroviral-mediated gene transfer into hepatocytes in vivo" Proc. Natl. Acad. Sci. USA 88:8377-8381 (1991).	<input type="checkbox"/>
	2	FOTEDAR ET AL., "Apoptosis and the cell cycle" Prog. Cell Cycle Res. 2:147-163 (1996).	<input type="checkbox"/>
	3	GASSMANN ET AL., "Maintenance of an extrachromosomal plasmid vector in mouse embryonic stem cells" PNAS USA 92:1292-1296 (1995).	<input type="checkbox"/>
	4	GenBank Accession No. M13994, "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-2-beta protein" Oct. 31, 1994.	<input type="checkbox"/>
	5	GenBank Accession No. M13995, "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-2-beta protein" Oct. 31, 1994.	<input type="checkbox"/>
	6	GenBank Accession No. U55763, "Cloning vector pEGFP-C1, complete sequence, enhanced green fluorescent protein (egfp) and neomycin phosphotransferase genes" June 15, 1996.	<input type="checkbox"/>
	7	HAMM ET AL., "Incorporation of 2'-Deoxy-2'-mercaptocytidine into Oligonucleotides via Phosphoramidite Chemistry" J. Org. Chem. 62:3415-3420 (1997).	<input type="checkbox"/>
	8	HANAHAN ET AL., "The Hallmarks of Cancer" Cell 100:57-70 (2000).	<input type="checkbox"/>
	9	HARRIS ET AL., "The Eu-myc Transgenic Mouse A Model for High-incidence Spontaneous Lymphoma and Leukemia of Early B Cells" J. Exp. Med. 167(2):353-371 (1988).	<input type="checkbox"/>
	10	HSU ET AL., "Immunogenicity of Recombinant Adenovirus-Respiratory Syncytial Virus Vaccines with Adenovirus Types 4, 5, and 7 Vectors in Dogs and a Chimpanzee" J. Infectious Disease 166:769-775 (1992).	<input type="checkbox"/>
	11	HUBER ET AL., "Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy" Proc. Natl. Acad. Sci. USA 88:8039-8043 (1991).	<input type="checkbox"/>

Receipt date: 09/16/2008 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10612179
	Filing Date		2003-07-02
	First Named Inventor	ROLAND KREUTZER	
	Art Unit	1635	
	Examiner Name	TRACY ANN VIVLEMORE	
	Attorney Docket Number	A2038-706120	

T.V.	12	HWU ET AL., "Functional and Molecular Characterization of Tumor-Infiltrating Lymphocytes Transduced with Tumor Necrosis Factor-alpha cDNA for the Gene Therapy of Cancer in Humans" J. Immunol. 150:4104-4115 (1993).	<input type="checkbox"/>
	13	JAMES ET AL., "The Therapeutic Potential of Ribozymes" Blood 91:371-382 (1998).	<input type="checkbox"/>
	14	KABANOV ET AL., "A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells" FEBS Lett. 259 (2):327-330 (1990).	<input type="checkbox"/>
	15	KAY ET AL., "Hepatic Gene Therapy: Persistent Expression of Human alpha1-Antitrypsin in Mice after Direct Gene Delivery In Vivo" Human Gene Therapy 3:641-647 (1992).	<input type="checkbox"/>
	16	KOVALCHUK ET AL., "Burkitt Lymphoma in the Mouse" J. Exp. Med. 192:1183-1190 (2000).	<input type="checkbox"/>
	17	KREPELA, "Cysteine proteinases in tumor cell growth and apoptosis" Neoplasma 48:332-349 (2001).	<input type="checkbox"/>
	18	KREUTZER ET AL., Specific Inhibition of Viral Gene Expression by Double-Stranded RNA in vitro. Annual Fall Meeting of the GBH, 1999-09-05, Abstract Nr. 328.	<input type="checkbox"/>
	19	KREUTZER ET AL., Specific inhibition of viral gene expression by double-stranded RNA in vitro. Sept. 8, 1999. Annual Fall Meeting of GBH, Poster 328.	<input type="checkbox"/>
	20	LETSINGER ET AL., "Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture" PNAS USA 86:6553-6556 (1989).	<input type="checkbox"/>
	21	LI ET AL., "Folate-Mediated Targeting of Antisense Oligodeoxynucleotides to Ovarian Cancer Cells" Pharm. Res. 15 (10):1540-1545 (1998).	<input type="checkbox"/>
	22	LUO ET AL., "The Gene-Silencing Efficiency of siRNA is Strongly Dependent on the Local Structure of mRNA at the Targeted Region" Biochemical and Biophysical Research Communications, Vol. 318(1):303-10 (2004).	<input type="checkbox"/>

Receipt date: 09/16/2008 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10612179
	Filing Date		2003-07-02
	First Named Inventor	ROLAND KREUTZER	
	Art Unit	1635	
	Examiner Name	TRACY ANN VIVLEMORE	
	Attorney Docket Number	A2038-706120	

IT.V./	23	MANOHARAN, "Oligonucleotide Conjugates as Potential Antisense Drugs with Improved Uptake, Biodistribution, Targeted Delivery and Mechanism of Action: Antisense and Nucleic Acid Drug Development 12:103-128 (2002).	<input type="checkbox"/>
	24	MANOHARAN ET AL., "Chemical Modifications to Improve Uptake and Bioavailability of Antisense Oligonucleotides" Ann. NY Acad. Sci. 660:306-309 (1992).	<input type="checkbox"/>
	25	MANOHARAN ET AL., "Introduction of a Lipophilic Thioether Tether in the Minor Groove of Nucleic Acids for Antisense Applications" Bioorg. Med. Chem. Lett. 3(12):2765-2770 (1993).	<input type="checkbox"/>
	26	MANOHARAN ET AL., "Cholic Acid-Oligonucleotide Conjugates for Antisense Applications" Bioorg. Med. Chem. Lett. 4(8):1053-1060 (1994).	<input type="checkbox"/>
	27	MANOHARAN ET AL., "Oligo Acid-Oligonucleotide Conjugates Alteration of the Pharmacokinetic Properties of Antisense Agents" Nucleosides & Nucleotides 14:969-973 (1995).	<input type="checkbox"/>
	28	MANOHARAN ET AL., "Lipidic Nucleic Acids" Tetrahedron 36:3651-3654 (1995).	<input type="checkbox"/>
	29	MARU, "Molecular Biology of Chronic Myeloid Leukemia" Int. J. Hematol. 73:308-322 (2001).	<input type="checkbox"/>
	30	MATRISIAN, "Cancer biology: Extracellular proteinases in malignancy" Curr. Biol. 9(20):R776-778 (1999).	<input type="checkbox"/>
	31	MENDELSON ET AL., "The EGF receptor family as target for cancer therapy" Oncogene 19(56):6550-6565 (2000).	<input type="checkbox"/>
	32	MIGNATTI ET AL., "Biology and Biochemistry of proteinases in Tumor Invasion" Physiol. Rev. 73:161-195 (1993).	<input type="checkbox"/>
↓	33	MISHRA ET AL., "Improved leishmanicidal effect of phosphorothioate antisense oligonucleotides by LDL-mediated delivery" Biochem. Biophys. Acta. 1264:229-237 (1995).	<input type="checkbox"/>

Receipt date: 09/16/2008 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10612179
	Filing Date		2003-07-02
	First Named Inventor	ROLAND KREUTZER	
	Art Unit	1635	
	Examiner Name	TRACY ANN VIVLEMORE	
	Attorney Docket Number	A2038-706120	

/T.V./	34	MUELLAUER ET AL., "Mutations in apoptosis genes: a pathogenetic factor for human disease" Mutat. Res. 488:211-231 (2001).	<input type="checkbox"/>
	35	MUZYCZKA, "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells" Curr. Topics Micro. Immunol. 158:97-129 (1992).	<input type="checkbox"/>
	36	NORMANNO ET AL., "The role of EGF-Related Peptides in Tumor Growth" Front. Biosci. 6:D685-707 (2001).	<input type="checkbox"/>
	37	OBERHAUSER ET AL., "Effective incorporation of 2'-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol" Nucl. Acids Res. 20:533-538 (1992).	<input type="checkbox"/>
	38	OBIKA ET AL., "Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2'-O,4'-C-methyleneribonucleosides" Tetrahedron 39:5401-5404 (1998).	<input type="checkbox"/>
	39	OUCHI ET AL., "Synthesis and Antitumor Activity of Poly(Ethylene Glycol)s Linked to 5-Flurouracil via a Urethane or Urea Bond" Drug Design and Discovery 9:93-105 (1992).	<input type="checkbox"/>
	40	PANDOLFI, "In vivo analysis of the molecular genetics of acute promyelocytic leukemia" Oncogene 20:5726-5735 (2001).	<input type="checkbox"/>
	41	PHILLIPS ET AL., "The NZB Mouse as a Model for Chronic Lymphocytic Leukemia" Cancer Res. 52:437-443 (2000).	<input type="checkbox"/>
	42	PILS, W. ET AL., "Flexible non-nucleotide linkers as loop replacements in short double helical RNAs," Nucleic Acids Research, 28(9): 1869-1963 (2000).	<input type="checkbox"/>
	43	POLLOCK ET AL., "Mouse models of acute promyelocytic leukemia" Curr. Opin. Hematol. 8:206-211 (2001).	<input type="checkbox"/>
↓	44	POLUSHIN ET AL., "Synthesis of Oligonucleotides Containing 2'-Azido- and 2'-Amino-2'-deoxyuridine Using Phosphotriester Chemistry" Tetrahedron 37:3227-3230 (1996).	<input type="checkbox"/>

Receipt date: 09/16/2008 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10612179
	Filing Date		2003-07-02
	First Named Inventor	ROLAND KREUTZER	
	Art Unit	1635	
	Examiner Name	TRACY ANN VIVLEMORE	
	Attorney Docket Number	A2038-706120	

/T.V./	45	RAVASIO, "Selective Hydrogenations Promoted by Copper Catalysts. 1. Chemoselectivity, Regioselectivity, and Stereoselectivity in the Hydrogenation of 3-Substituted Steroids" J. Org. Chem. 56:4329-4333 (1991).	<input type="checkbox"/>
	46	REED, "Mechanisms of Apoptosis" Am. J. Pathol. 157:1415-1430 (2000).	<input type="checkbox"/>
	47	REGO ET AL., "Analysis of the Molecular Genetics of Acute Promyelocytic Leukemia in Mouse Models" Semin. in Hemat. 38:54-70 (2001).	<input type="checkbox"/>
	48	ROSENFELD ET AL., "Adenovirus-Mediated Transfer of a Recombinant a-Antitrypsin Gene to the Lung Epithelium in Vivo" Science 252:431-434 (1991).	<input type="checkbox"/>
	49	ROSENFELD ET AL, "In Vivo Transfer to the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium" Cell 68:143-155 (1992).	<input type="checkbox"/>
	50	SAISON-BEHMOARAS ET AL., "Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation" EMBO J. 10:111-118 (1991).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Tracy Vivlemore/	Date Considered	04/24/2009
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.